Affected patients have mutations of the interleukin-2 (IL-2) receptor y chain gene. Using Epstein-Barr virus-transformed B-lymphoblastoid cell lines (B-LCLs) established from two unrelated XSCID patients, we could show that neither expressed the IL-2 receptor y chain on the cell surface. A novel cytokine IL-15, which has biologic activities similar to those of IL-2, could bind to the XSCID B-LCLs in the absence of T HE CLINICAL FEATURES of X-linked severe combined immunodeficiency (XSCID) include recurrent infections, failure to thrive accompanied by markedly reduced or absent T cells, and normal numbers of B ce1ls.l~' The chromosomal location of the gene responsible for this disease has been mapped to Xq13.6,7 Recently, the interleukin-2 (IL-2) receptor y chain has been cloned8 and the gene mapped to the same I O C U S .~~~~
IL-2 and IL-15. However, several mouse cell lines, such as an IL-3-dependent myeloid cell line, 32D, and a CD3-CD4-CD8-pre-T-cell line, cannot respond to IL-15, although they can bind IL-2 with high affinity and respond to it.I9.2O The mouse IL-2 receptor P y heterodimer has been shown to lack IL-2 binding ability;2' similarly, the mouse f l y heterodimer is predicted to lack IL-15 binding ability." Because IL-15 shows strong binding and potent biologic activity on other IL-2-dependent cell lines, there may exist an additional receptor component that specifically binds IL- In the present study, we have established B-LCLs from two unrelated XSCID patients, characterized the y chain mutations, and shown that IL-15 can bind to the B lymphoblasts lacking cell surface expression of the y chain. However, B lymphoblasts from XSCID patients are unable to internalize IL- 15 efficiently, in contrast to normal control cells. These data show that a novel IL-15-specific receptor component is expressed by the B-lymphoblastoid cell lines (B-LCLs) and that the y chain is not necessary for IL-15 binding but is required for IL-15 internalization.
MATERIALS AND METHODS

Patients
Family 1. Patient no. I (111-9) and his maternal cousins (111-1 and 111-3; Fig 1 j presented with failure to thrive, diarrhea, candida infections, and lymphopenia during the first few months of life. III-1 died at the age of 8 months of pseudomonas sepsis. Lymphocyte marker analysis of patient no. 1 (111-9) and his cousin 111-3 showed a markedly decreased T-cell population and normal numbers of B lymphocytes. Both had low or absent serum Ig levels, and in vitro lymphocyte proliferation in response to mitogens, allogenic cells, and specific antigens was absent. 111-3 died after unsuccessful bone marrow transplantation at 1 year of age. At autopsy, both brothers, 111-1 and 111-3, had the classical features of XSCID, including thymi that were small, and lacked Hassall's corpuscles.',' Patient no. I (111-9j, who developed severe chronic graft-versus-host disease after receiving a bone marrow transplant from an HLA-identical sister, died at 5 years of age of complications from this procedure. When analyzed shortly before his death, 90% of patient 111-9's lymphocytes were of male (recipient) karyotype. An Epstein-Barr virus (EBV)-induced B-LCL obtained at that time had an exclusively XY karyotYPe.
Family 2. Patient no. 2 (111-2) was born in 1977 to a mother whose nine brothers allegedly all died of infections during the first year of life. His older brother (111-1) died at the age of 1 year of disseminated herpes simplex infection after having had diarrhea most of his life. Patient no. 2 developed recurrent infections during the newborn period, had hypogammaglobulinemia and normal numbers of circulating lymphocytes that were all surface Ig positive, and failed to respond to immunizations. The patient died at the age of 7 months with disseminated adenovirus infection. At autopsy, patient no. 2 (111-2) had a small thymus that lacked Hassall's Corpuscles and hypoplastic lymphoid tissues. 
RNA Blot Analysis
Isolation of RNA and Northern blot analysis were performed as described previously." Briefly, total RNAs were isolated from cell lines by extraction with guanidinium thiocyanate and aliquots of 5 pg of total RNA were electrophoresed in a 1.2% agarose gel containing 0.35 m o m formaldehyde for 3 hours at 150 mA and transferred to Hybond-N (Amersham Corp, Arlington Heights, IL) with 20X SSC. The blot was hybridized with the antisense y chain RNA probe transcribed with T3 RNA polymerase. After hybridization, the filter was extensively washed with 0.15X SSC containing 0.1 % sodium dodecyl sulfate (SDS) at 63°C for 30 minutes.
Sequencing Analysis of cDNA and Genomic DNA
Single-strand cDNA of patient no. 1 (111-9) was obtained from mRNA prepared from the B-LCL using a Superscript Preamplification System for First Strand cDNA Synthesis (GIBCO BRL, Grand Island, NY) and subjected to polymerase chain reaction (PCR) in 100 pL of 50 mmol/L KC1, 10 mmol/L Tris-HC1 (pH 8.3), 1.5 mmoY L MgCl,, 1 pmol/L primers 2 and 15 (Table l) , 200 pmoVL dNTPs, and 2.5 U Taq DNA polymerase (Boehringer Mannheim, Indianapolis, IN). Samples were denatured for 5 minutes at 94°C and then amplified for 30 cycles of I minute each at 9 4 T , 6 0 T , and 72% with a final extension performed for 5 minutes at 72°C. The PCR product was purified by gel filtration and subcloned into pBluescript (Stratagene, La Jolla, CA), generating pBlue:IL-2Ry-NU, for sequencing. The sequences were determined using the AB1 Taq DyeDeoxy Terminator Cycle Sequencing kit on an automated Applied Biosystems DNA sequencer, model 373A (The Perkin-Elmer Corp, Foster City, CA). Both strands were sequenced. The point mutation of this patient was confirmed by genomic sequencing. For this purpose, genomic DNA was isolated from 200 pL of frozen whole blood using the QIAamp Blood Kit (Qiagen Inc. Chatsworth, CA). A "touch-down" PCR was performed as described previously'" to amplify the segment of interest using 200 ng of template DNA and primers IO and 14 (Table l) . Briefly, the template was denatured in buffer for 30 minutes at 94°C. and the remaining reagents were then added at 80°C. Subsequently, 10 PCR cycles with stepwise annealing temperatures from 72°C to 62°C were performed, followed by 25 cycles with annealing temperature at 61°C. The resultant PCR prodFor personal use only. on October 3, 2017. by guest www.bloodjournal.org From 
Expression Plasmid Construction and Transfection
The expression vector for the human L-2 receptor y chain, pDC409:IL-2Ry, has been described previo~sly.'~ The coding region for the y chain of patient no. 1 (111-9) was excised from pB1ue:IL2Ry-NU and subcloned into the Sal I and No? I sites of p m 4 0 9 yielding pDC409:IL-2Ry-NU. The mutated and normal y chains were transiently expressed by the diethylaminoethyl (DEAE)-dextran method similar to the previous de~cription.'~ Briefly, Lab-Tek one-chambered slides or two-chambered coverslip glasses (Nunc Inc, Naperville, L) were pretreated with 10 ng/mL fibronectin-like engineered protein polymer (Sigma, St Louis, MO) and COS-7 cells were seeded. For one-chambered slides, the cells were incubated with 2 p g of DNA and 25 pL of DEAE-dextran (4 mg/mL in PBS) in the medium containing 0.1 mmolR. chloroquine for 3 hours at 37°C and then shocked by 10% dimethylsulfoxide (DMSO) for 10 minutes at room temperature on the following day. For two-chambered coverslip glasses, reagents added were half the amounts of those used for one-chambered slides. The cells were further cultured at 37°C for 2 days.
Confocal Microscopy
Transfected COS-7 cells grown on glass coverslips were washed with PBS and fixed with 4% paraformaldehyde containing 0.1% Triton X-100 at room temperature for 30 minutes. Triton was left out for surface staining of cells. Autofluorescence was quenched by treatment with 50 mmol/L W C 1 for 10 minutes. Cells were incubated for 1 hour in PBS containing 5% normal goat serum ? 0.1% Triton X-100 to block nonspecific binding and permeabilize cells.
The cell preparations were then incubated in primary antibody (TUGM) at a 1:200 dilution of ascites fluid for 1 hour. After three washes with PBS ? 0.1% Triton X-100, cells were incubated for 1 hour in Texas red-conjugated goat antirat secondary antibody (Jackson Immunoresearch, West Grove, PA) at a 1:200 dilution. All cell preparations were then incubated for 1 hour in PBS containing 5% normal goat serum and 0.1 % Triton X-100 followed by the addition of 10 nmol/L YOYO-l (Molecular Probes, Eugene, OR) for nucleic acid counterstaining. After washing, cells were mounted in 100 mg/ 
IL-15 Binding Analysis
Radiolabeling of L-15 and IL-2 and binding conditions were the same as described previou~ly.~~ Briefly, B-LCLs established from XSCID patients and normal controls or transfected COS-7 cells were incubated with '*'I-labeled IL-15 or L -2 at 4°C for 60 minutes in the presence of 0.02% sodium azide to avoid internalization.
IL-15 Internalization
The B-LCLs were incubated with SO0 pmol/L '2sI-labeled 1L-15 at 4°C for 30 minutes, washed, and further incubated at 37°C for the indicated times. They were then centrifuged and treated with chilled 0.05 m o m glycine (pH 3.0) containing 150 mmol/L NaCl for S minutes. The radioactivities of the supernatant fraction, acidremovable glycine buffer fraction, and acid-unremovable cell precipitate were counted separately.
RESULTS
Characterization of y Chains in XSCID Patients
IL-2 receptor y chains of two unrelated XSCID patients were analyzed. The pedigrees of the two families are shown in Fig 1. Affected male subjects of both families had characteristic clinical and laboratory findings (see Materials and Methods).
Flow cytometry profiles indicate that B-LCLs established from the two XSCID patients (111-9 of family 1 and 111-2 of family 2) failed to express the IL-2 receptor y chain, although normal control B-LCLs clearly expressed the y chain (Fig 2A) . The y chain mRNA expression, determined by hybridization to the full-length coding region of the y chain, was normal in size and amount in B-LCLs established from patient no. 1 (In-9) when compared with that of the normal control (Fig 2B) . In contrast, no detectable y chain transcripts were observed in a B-LCL established from patient no. 2 (111-2; Fig 2B) .
Sequence analysis of cDNA isolated from B-LCLs of patient no. l (In-9) using reverse-transcriptase PCR (RT-PCR) showed a C to T point mutation at nucleotide position 690 resulting in the substitution of arginine (Arg)*04 by cysteine (Cys) in the extracellular region near the WSXWS motif (Fig 3) .* This mutation was confirmed by direct sequencing of PCR-amplified genomic DNA from patient no. 1 with primers 10 and 14 (Table 1) . Because the B-LCL established from patient no. 1 did not express the y chain on the cell surface even though mRNA expression was comparable to the normal control, we examined the mutant y chain distribution by confocal microscopy in transiently transfected COS-7 cells, comparing it with the wild-type y chain distribution. As shown in Fig 4-1 , the mutant y chain could not be detected by an antihuman L 2 receptor y chain monoclonal antibody, TUGh4, on the cell surface of the transfected COS-7 cells. This result was in sharp contrast to that obtained with the wild-type y chain, which was clearly stained by TUGh4 on the transfected cells. However, the mutant y chain of patient no. 1 was stained by the antibody after permeabilization of the transfected cells with detergent, as was the wild-type y chain (Fig 4-11) . These data show that the Arg204Cys substitution results in a defect in cell surface expression of the y chain. On request of the family of patient no. 1, we analyzed, using direct sequencing, PCR-amplified genomic DNAs obtained from seven female members of that family and found four carriers, including the 2 obligate carriers (the sisters II-4 and 11-6, who had affected sons). DNA analysis showed that the propositus (111-9) had a T and the normal control a C at position 690, and that the camers had a mixture of C and T (data not shown).
In patient no. 2 (111-2), only PCR-based direct genomic sequencing of the y chain could be performed; repeated attempts to amplify a full-length cDNA by RT-PCR were unsuccessful. The y chain of patient no. 2 showed a deletion of 7 nucleotides from positions 270 to 277 causing a frameshift followed by substitution of 25 amino acids and a cc cc premature stop codon in the extracellular domain (Fig 3) . This mutation is located between the second and third of the four conserved cysteine residues that are characteristic of the hematopoietin receptor family.'
IL-15 Binds to But Is Not Internalized EfJiciently by BLCLs Established From XSCID Patients
We have previously shown that the human IL-2 receptor p chain alone can not bind IL-15 and that coexpression of the y chain is required for IL-15 binding to transfected COS-7 cells.'" Furthermore, as shown here, COS-7 cells transiently transfected with the mutant y chain derived from patient no. 1 (111-9) together with the human p chain could not bind IL-2 or IL-15 (Fig 5) . This observation is consistent with the lack of surface expression of the mutant y chain (Fig 2A and 4-1) . Because almost all cells of lymphoid origin express constitutively the IL-2 receptor y chain, it is difficult to evaluate the binding properties of an IL-15-specific subunit. Because B-LCLs established from the XSClD patients lack cell surface expression of the y chain, they are ideal In previous studies, it was shown that the y chain was required for IL-2 and IL-7 internalization.'.'s We therefore examined whether the y chain also plays an important role in IL-15 internalization. For this purpose, internalization of IL-15 by B-LCLs established from normal controls and the two XSClD patients (111-9 and 111-2) was compared. In the normal control B-LCLs, IL-15 was internalized significantly within 5 minutes after incubation of cells at 37°C and reached a maximum level within 20 to 30 minutes (Fig 7) . In contrast, delayed and inefficient internalization was observed in the BLCLs established from both XSCID patients (Fig 7) . These findings suggest that the IL-2 receptor y chain is essential for IL-15 internalization and that the IL-15-specific binding receptor subunit is insufficient for IL-15 internalization in the absence of the y chain.
DISCUSSION
Although at least I8 different mutations of the gene coding for the IL-2 receptor y chain have been identified in XSCID patients, the functional properties of the mutant y chains have not been systematically examined.'"' In the present study, we have characterized mutations in the y chain from two unrelated XSCID patients and examined their effects on binding and internalization of the newly identified cytokine IL-15 by B-LCLs established from these patients.
A single amino acid substitution from ArgZM to Cys in the y chain results in the failure of y chain expression by B lymphoblasts derived from patient no. 1 (111-9), although expression of y chain mRNA is comparable to normal controls. The lack of detection of the mutant y chain on the cell surface was not due to antigenic alteration of the epitope detected by the antihuman IL-2 receptor y chain monoclonal antibody, TUGh4, because we were able to detect the mutant y chain readily inside permeabilized COS-7 cells transiently transfected with the mutant y chain cDNA using confocal microscopy. This mutation is of interest because the single amino acid substitution (Arg204Cys) results in the lack of surface expression of the y chain. One possibility to consider is the formation of an intramolecular disulfide bond between the mutated Cys" and another cysteine residue in the extracellular domain of the y chain that alters the structure of the y chain. Alternatively, Arg"" may play an essential role in the transport of the y chain; the mutant y chain may be trapped in the Golgi apparatus and fail to be transported to the cell surface. The same point mutation was previously reported in an unrelated family," making it the only published example of an XSClD mutation that is not unique to a single family.
B lymphoblasts of patient no. 2 (111-2) failed to express y chain mRNA. This finding is not uncommon, because Puck et all" reported that 7 of 19 XSCID patients had absent or minimal IL-2 receptor y chain mRNA. In 2 of these cases, the mutations affecting the y chain were identified. One mutation, causing disruption of a splice donor site, was of y chain mFWA observed in the latter case can be excaused by a single nucleotide change in the exon 3/intron 3 plained by the fact that premature termination of translation junction. The other mutation, a point mutation in exon 2, leads to mRNA instability. The remarkable reduction of y resulted in a premature stop codon. The diminished amounts chain mFWA level in patient no. 2 can also be explained 
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by partial disruption of a splice donor site and premature translational termination because the seven nucleotide deletion is located adjacent to the exon Uintron 2 junction and the frameshifted y chain is expected to terminate 25 amino acids downstream from the site of the mutation. Because the encoded truncated y chain does not contain the transmembrane domain, it cannot be anchored on the cell surface; if synthesized, it would be a secreted form.
Because all cells of lymphoid origin express the y chain on their cell surface, we took advantage of the availability of patient B-LCLs that lacked surface expression of the y chain to study the role of the y chain in facilitating the binding of cytokines that use the y chain as part of their receptors. Because of its overlapping activity with IL-2, we have tested the binding properties and internalization of IL-15. As previously described, the human IL-2 receptor p chain itself is not able to bind IL-15 under physiologic conditions and the y chain is required in addition to the p chain for IL-15 binding by reconstituted COS-7 cells." Our finding that IL-15 could bind B-LCLs established from both XSCID patients lacking cell surface expression of the y chain suggested the existence of another L-15-specific receptor distinct from the P y heterodimer of the IL-2 receptor. In a previous study, we observed that fresh human venous endothelial cells bound L 1 5 with high affinity (kd = 33.3 pmoY L and 990 sites), although these cells could not bind IL-2.I9 Taken together, these data suggest that there is an IL-15-specific binding protein in human cells. The molecular nature of this novel human IL-15 receptor is currently under investigation.
The B-LCLs were also used to examine IL-15 internalization, because internalization of IL-2 and IL-7 has been reported to be one of the functions of the y chain.'.'' Normal control B-LCLs showed rapid and significant IL-15 internalization; in contrast, IL-15 was not internalized efficiently by B-LCLs established from the two XSCID patients. This experiment shows that the novel, as yet uncharacterized IL-15-specific receptor component is insufficient for rapid and efficient internalization and that the y chain is essential. It remains possible that the lack of IL-15 internalization and signaling may contribute to the phenotype of XSCID.
